<SEC-DOCUMENT>0001129928-11-000030.txt : 20110324
<SEC-HEADER>0001129928-11-000030.hdr.sgml : 20110324
<ACCEPTANCE-DATETIME>20110324140823
ACCESSION NUMBER:		0001129928-11-000030
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20110324
FILED AS OF DATE:		20110324
DATE AS OF CHANGE:		20110324

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ONCOLYTICS BIOTECH INC
		CENTRAL INDEX KEY:			0001129928
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-31062
		FILM NUMBER:		11708843

	BUSINESS ADDRESS:	
		STREET 1:		1167 KENSINGTON CRES NW SUITE 210
		STREET 2:		CALGARY ALBERTA CANADA T2N 1X7
		CITY:			ALBERTA CANADA
		STATE:			A0
		ZIP:			00000
		BUSINESS PHONE:		4036707380

	MAIL ADDRESS:	
		STREET 1:		210 - 1167 KENSINGTON CRES NW
		CITY:			CALGARY
		STATE:			A0
		ZIP:			T2N 1X7
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>form6-k.htm
<DESCRIPTION>6K FORM
<TEXT>
<html>
<head>
    <title>form6-k.htm</title>
    <!-- Licensed to: Oncolytics Biotech Inc. -->
    <!-- Document Created using EDGARizer 5.2.3.0 -->
    <!-- Copyright 1995 - 2009 Thomson Reuters. All rights reserved. -->
</head>

<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SECURITIES AND EXCHANGE COMMISSION</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Washington, D.C. 20549</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 18pt; FONT-WEIGHT: bold">Form 6-K</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Report of Foreign Private Issuer</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Pursuant to Rule&#160;13a-16 or 15d-16</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">of the Securities Exchange Act of 1934</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">For the month of&#160;March 2011</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Commission File Number 000-31062</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">Oncolytics Biotech Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Translation of registrant&#8217;s name into English)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Suite&#160;210, 1167 Kensington Crescent NW</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Calgary, Alberta, Canada T2N 1X7</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Address of principal executive offices)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark whether the registrant files or will file annual reports under cover Form&#160;20-F or Form&#160;40-F.</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="38%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Form&#160;20-F&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: wingdings">&#254;</font></font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="38%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Form&#160;40-F&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: wingdings">o</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark if the registrant is submitting the Form&#160;6-K in paper as permitted by Regulation&#160;S-T Rule&#160;101(b)(1):&#160;&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">o</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Note: </font>Regulation&#160;S-T Rule&#160;101(b)(1) only permits the submission in paper of a Form&#160;6-K if submitted solely to provide an attached annual report to security holders.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark if the registrant is submitting the Form&#160;6-K in paper as permitted by Regulation&#160;S-T Rule&#160;101(b)(7):&#160;&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">o</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Note: </font>Regulation&#160;S-T Rule&#160;101(b)(7) only permits the submission in paper of a Form&#160;6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant&#8217;s &#8220;home country&#8221;), or under the rules of the home country exchange on which the registrant&#8217;s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant&#8217;s security holders, and, if discussing a material event, has already been the subject of a Form&#160;6-K submission or other Commission filing on EDGAR.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule&#160;12g3-2(b) under the Securities Exchange Act of 1934.</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="38%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Yes&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: wingdings">o</font></font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="38%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">No&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: wingdings">&#254;</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">If &#8220;Yes&#8221; is marked, indicate below the file number assigned to the registrant in connection with Rule&#160;12g3-2(b):&#160;&#160;&#160;82&#160;-&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="7%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">EXHIBIT</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NUMBER</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="69%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">DESCRIPTION</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="69%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">99.1</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="69%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">News Release Dated&#160;&#160;March 24, 2011 -&#160;Oncolytics Biotech&#174; Inc. Completes Patient Enrollmentin U.S. Phase 2 Clinical Trial Investigating REOLYSIN<font style="DISPLAY: inline; FONT-FAMILY: times new roman">&#174;</font> in Combination with Paclitaxel and Carboplatin in Head and Neck Cancers</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SIGNATURES</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="36%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="3" valign="top" width="39%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Oncolytics Biotech Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Registrant)</font></div>
</td>
</tr><tr>
<td align="left" valign="middle" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="36%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="36%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="middle" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="36%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="38%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Date:&#160;&#160;March 24, 2011</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">By:</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="36%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">/s/&#160;&#160;Brad Thompson</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Brad Thompson</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Presiden &amp; Chief Executive Officer</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<br>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex99.htm
<DESCRIPTION>RELEASE
<TEXT>
<html>
<head>
    <title>ex99.htm</title>
    <!-- Licensed to: Oncolytics Biotech Inc. -->
    <!-- Document Created using EDGARizer 5.2.3.0 -->
    <!-- Copyright 1995 - 2009 Thomson Reuters. All rights reserved. -->
</head>


<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><img src="ex993.jpg" alt=""></font></div>

<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">210, 1167 Kensington Cr. N.W</font></div>

<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Calgary, Alberta</font></div>

<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Canada T2N 1X7</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div>
<hr style="COLOR: black" align="left" noshade size="3" width="100%">
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -18pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">FOR IMMEDIATE RELEASE</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Oncolytics Biotech<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">&#174;</font> Inc. Completes Patient Enrollment in U.S. Phase 2 Clinical Trial Investigating REOLYSIN<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">&#174;</font> in Combination with Paclitaxel and Carboplatin in Head and Neck Cancers</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">CALGARY, AB, --- March 24, 2011</font> - Oncolytics Biotech Inc. (&#8220;Oncolytics&#8221;) (TSX:ONC, NASDAQ:ONCY) today announced that it has completed patient enrollment in its U.S. Phase 2 clinical trial (REO 015) using intravenous administration of REOLYSIN in combination with paclitaxel and carboplatin in patients with advanced head and neck cancers.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8220;This study was performed in part to confirm the results of our UK Phase II study, which enrolled a slightly different patient population, and to support our ongoing Phase III study in platinum resistant head and neck cancers,&#8221; said Dr. Brad Thompson, President and CEO of Oncolytics.&#160;&#160;&#8220;This U.S. study examined a greater proportion of patients with prior taxane exposure than either of the other two studies we have conducted in this indication.&#8221;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">This trial was a 14-patient, single arm, open-label, dose-targeted, non-randomized trial of REOLYSIN given intravenously in combination with a standard dosage of paclitaxel and carboplatin.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font><br>
&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Eligible patients included those with advanced or metastatic head and neck cancers that were refractory to standard therapy or for which no curative standard therapy existed. The primary objective of the Phase 2 trial was to measure tumor responses and duration of response, and to describe any evidence of antitumor activity. The secondary objective is to determine the safety and tolerability of REOLYSIN when administered in combination with paclitaxel and carboplatin to patients with advanced or metastatic head and neck cancers. The results are expected to be fully reported in 2011.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">About Oncolytics Biotech Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics.&#160;&#160;Oncolytics&#8217; clinical program includes a variety of human trials including a Phase III trial in head and neck cancers using REOLYSIN, its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit: <font style="DISPLAY: inline; TEXT-DECORATION: underline">www.oncolyticsbiotech.com</font>.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company&#8217;s expectations related to the U.S. Phase 2 combination REOLYSIN/paclitaxel/carboplatin clinical trial for patients with advanced head and neck cancers, and the Company&#8217;s belief as to the potential of REOLYSIN as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company&#8217;s actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN as a cancer treatment, the tolerability of REOLYSIN outside a controlled test, the success and timely completion of clinical studies and trials, the Company&#8217;s ability to successfully commercialize REOLYSIN, uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company&#8217;s quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable laws.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">FOR FURTHER INFORMATION PLEASE CONTACT:</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="25%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The Equicom Group</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Nick Hurst</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">300 5<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">th</font> Ave. SW, 10<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">th</font> Floor</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Calgary, Alberta, T2P 3C4</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Tel: 403.218.2835</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Fax: 403.218.2830</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">nhurst@equicomgroup.com</font></font></div>
</td>
<td align="left" valign="top" width="27%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The Investor Relations Group</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Erika Moran</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">11 Stone St, 3rd Floor</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">New York, NY&#160;&#160;10004</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Tel:&#160;&#160;212.825.3210</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Fax:&#160;&#160;212.825.3229</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">emoran@investorrelationsgroup.com</font></font></div>
</td>
<td valign="top" width="28%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">-30-</font></div>

<br>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex993.jpg
<TEXT>
begin 644 ex993.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`!X`?0#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W^BBB@`HH
MJ.21(8GED=4C0%F9C@*!U)-`$E%<7J_Q%TRPE\FQB:_=3AF5MD8ZYPV#D\#H
M,<]:XZ^\?Z_>;@EQ':HR;"L$8'XY.6!^AK-U(H=CV6BO%O\`BM/^H_\`^1J/
M^*T_ZC__`)&J?:^06/::*\<M?'?B+393#/*LWE#RC%=1<J1ZD8;=QW-=/I/Q
M+L[AECU.W:U;`S-'ET)QSD8R/;[W7\:I5(L+'>45''(DT22QNKQN`RLIR&!Z
M$&I*T$%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%
M%%`!1110`4444`%%%%`!1110`4450U75K31K![R\DV1KP`.6=NRJ.Y_SVI-V
M`AUS7['P_:+/>NQ+G"11C+OZX'M_GJ*\HU'5-9\9:H8HHII$)!CM8B2D8Z!C
MV_BY8^O8<5'(=3\9^(V,:L\LK':&;Y8(\\9..%&?3D^YKUO0]`L?#]HT%DC$
MN<O+(<N_ID^W^>IK'6H_(K8Y;1OAK;0XEU>?[2__`#QA)5._5OO'L>WXUV-A
MI=CID6RRM(;=2`I,:8+8Z;CU;ZFKM%:J"6Q-PHHHJ@*MWI]E?;/MEG;W&S.W
MSHE?;GKC/TKAO$'PXC=3/H9\MQDM;ROD$8_A8\YS_>..>HQ7H=%3*"EN%SP_
M2-;U7PKJ.PK,B*<S6<V5#9`_A/W6QC!^G;BO6-`\06GB'3Q<6YVR+@30D_-&
MW]1Z'O\`F*-;\.:=KT.R\BQ(,;9XP!(H';..G)X/'->3R#4_!GB-A&S)+$QV
MEE^6>//&1GE3CUX/N*RUI^A6Y[A15#2M6M-9L$O+.3?&W!!X9&[JP['_`#WJ
M_6R=R0HHHI@%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%
M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`44
M44`%%%%`!1110`4444`%>3_$76_MVK+IT+Y@M/OX/#2'KWQP./4'=7I>IWZ:
M9I=U>R;2((V<!FV[CV7/N<#\:\G\$63:MXNBFG;S/)W74AD<[F8'@Y[G<RGG
MWK&H[VBAH]%\)>'UT#1UC<9NYL23D@9#8^YD=E^O7)[UT%%%:I65A!1113`*
M***`"BBB@`KE/&_AP:UIAN;>-?MUL"RD*2TB#.4X_,=>?3)KJZ2I:NK,#R3P
M#K[:;JRZ?*<VMZX49)^23H"![\`_ASQ7K=>-^/=-BT[Q1*83\MT@N"O]UF)#
M=^<E2?QKU;1[[^TM'L[TM&6FA5W\L_*&Q\P_`Y%9TG9N+&R_1116P@HHHH`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB
M@#DOB)=?9_";Q;-WVF9(LYQMP=^??[F/QK.^%UKLTZ_O-^?-F6+9CIM7.<^^
M_P#2K/Q._P"1;MO^OQ?_`$!Z/AC_`,BW<_\`7XW_`*`E8_\`+P?0[6BBBMA!
M1110`4444`%%%%`!1110!P?Q/M4?2;*Z);S(YS&H[8923_Z`/UJU\-IY9O"[
MH[96&X=(QC[HPK8_-C^=,^)W_(MVW_7XO_H#T?#'_D6[G_K\;_T!*Q_Y>#Z'
M:USOC#7;KP_I,5W:1PO(\XC(E!(P58]B/2NBKBOB=_R+=M_U]K_Z`]7-V3!&
M3I7Q,N6OT35;>!+5OE:2!6W(?7!)R/;K_(^CQR)-$DL;J\;@,K*<A@>A!KRC
M1_#C^(O!4CP;3?6MTPA+D_-'M4F//;EB1[YZ9)IOA+Q;-X>N3IVHB3[%O*LK
M`[K=L\\=<9ZK^(YR#G";7Q!8]*UZ\O-/T2[O+&*.2>%-X63[NT'YB>1T7)KF
MO!_C#4/$&KRVEU#;)&D#2@Q*P.0RCNQ]:Z/7)$F\+:E+&ZO&]E*RLIR&!0X(
M->>?#'_D9;C_`*]&_P#0TJI-\R!+0]8HHK!\7:P^B>'YKF%U2Y=ECA++N^8_
MX*&//'%:-V5Q$6O>,=-T%G@D9I[P#/D1]L@XW-T7M[\@XK$M?$GC+4]\UCH5
MN(#AD,RLN5/W<,S*&X[BN>\"::FL>(Y9[Z)KF.*-I',B[U9V./GR#G.6/U7V
MKU^LXWGJ/8X4ZGX^MX7=]'M)`NYR<AFQR<`*_..@XS]36]H.KZEJWFO=Z-)I
M\2<*9I#O<^RE1Q[_`,^<;=%4HM=0%JO>7D%A:275U*L4$0RSMV_Q^E6*\G^(
M^JRW&NC3EDD$%LBEHSPID(SN]_E91S[_`(DY<JN"-J7Q_=ZE<QVOAW29)Y3@
ML9US@9QT4\#E?F+8JS_:7C__`*`EA_WV/_CM:?@K3AIWA:T&%\RX7[0Y4DYW
M?=Z_[.T?A70TE%M7;`X*Z\7>)M"V2ZUHD`@DRJ&&3;\W7EMS#IGCO^%=%HWB
MK2==PEK<;+@_\L)OE?OT[-P,\$X[XK8DC2:)XI$5XW!5E89#`]01Z5X1?PRZ
M'XAGB@,D;VER3"TB_-A3E&Z8/&#TP:F3<`6I[W15>RNDOK&"[B#+'/&LBANH
M##(S^=6*UOH(\\\->.M4UCQ!:V%Q!:)%+OW-&C!N$+=V/I7H=>+>!/\`D<]/
M_P"VG_HMJ]IK.DVUJ-A1116HCA_%/B3Q#X=N]RVUE+8R-^ZF,;\?[+?-][^?
MY@:WA;Q3!XBM=K!8[Z(?O80>O^TO^S_+\B=J\L[>_M)+6ZB66"489&[_`.'U
M[5Y%KV@W_@[58KRSED^S[\V]R.JG^ZW;.,^S#\0,I-Q=^@]SV6N2\6^,X]!Q
M:6BQSWYP65\E8E_VL=SV'X^F<6Z^)6_0$^SP>7JKY1^,I'_MCUSV';G.<?-#
MX/\`![ZC*-9UE6>)SYD<4O)F)YWOG^'_`-"^GWASYM(A;N=5X6U'6]6M/MNI
MP6UO;R#]PD:,'?\`VCECA?3UZ].NIJTNH0Z9,^EP1SWHQY<<API^89SR.V>]
M7Z*NVEA'%?VEX_\`^@)8?]]C_P".UDZGXW\4:-<K;W^GV$,K)O"X+?+DC/#G
MT->EUY/\3O\`D9;?_KT7_P!#>LYIQ5TQHWK?6O'5U;17$&C6#12H'1MP&5(R
M#_K/>K^F7GC*?488]0TVRMK0G]Y*IW$#'8"3OT]LUL^'O^1;TK_KSB_]`%:-
M4H];@+7.^,-=NO#^DQ7=I'"\CSB,B4$C!5CV(]*Z*N*^)W_(MVW_`%]K_P"@
M/3F[18(L>"_$][XC^W?;(K=/(\O9Y*L,[MV<Y)_NUUM><_"O_F+?]L?_`&>O
M1J*;O&[!D<DB0Q/)(ZI&@+,['`4#J2?2N+U'XC688V^D6TU[<NP2,E2J$D<8
M'WCS@8P,^M4/B;JLJO:Z5')(B,GG3*/NN,X7WX*MQTZ?A=^'&D0QZ,=2FM8S
M<23-Y,S89@@&WC^[SO';/Y5+DW+E0!!K/CRYA65-"M`K9P)!Y;?]\M("*D_M
M_P`8V/[V_P##D<\1^4+:ME@?4X+\<'MZ<UVU%5RON*Y0TJ[N[VP2XO++[%(_
M(A,F]E';=P,'V_KP+]%%4!Q.I?$2TM]0^R:;9R:@X?9N1]H9N,!,`EN<CM[9
MS39-0\=WZ@6^EVUE%,04D=E+Q*3GY@6/;K\N>O&:Y_4?!>K:!J4=_IL7VZ""
M998P!N<8((#*,$\_W?3/%:MC\4(3A;_39$P@R\#AMS?[IQ@=>YK'F=_>=A^A
M.VM^.+"*%KO0XKB,,JN8AND?U/R,<$XZ[<?RK<T+7=2U>YE2ZT&XT^)$SYLS
MGYFSPH!4>_/M[U6L?'V@7F`]Q);.S[`L\9'XY&5`^I[5T=O<0W4*SV\T<T3?
M=>-@RGMU%7'R8$U%%%:".2^(MK]H\*/+OV_9IDEQC.[G9CV^_G\*SOA==;]-
MO[/9CRIEEWYZ[EQC'ML_6NQU.P34]+NK*3:!/&R`LN[:>S8]C@_A7D_@B];2
M?%T4,Z^7YVZUD$B'<K$\#'8[E4<^]8RTFF/H>RT445L(****`"BBB@`HHHH`
M****`.#^)]TB:396A#>9).9%/;"J0?\`T,?K5KX;02P^%W=UPLUR[QG/WAA5
MS^:G\JXSQ[J46H^*)1"/EM4%N6_O,I);MQ@L1^%>J:)IPTG1+2Q`4-%&`^TD
M@OU8C/JQ)K&.LVQ]#1KBOB=_R+=M_P!?:_\`H#UVM8?B?0/^$CTV.S^T_9]D
MPEW^7OS@$8QD?WJN:NK(2,;X8_\`(MW/_7VW_H"5-XQ\')K<9O;)53447IT$
MP'8_[7H?P/8C3\,>'_\`A'--DL_M/VC?,9=_E[,9"C&,G^[6Y24;QLQGB^C^
M([K2]/U'1;W<+:6":-4D!W0R%3QCW;@CL3GCG.A\,?\`D9;C_KT;_P!#2NO\
M2^"K3Q!.ERDOV2Z'#R*FX2#MD9'(]?3CTQ'X8\%_\(YJ4EY]O^T;X3%M\G9C
M)!SG<?2LU"2DAW.MK!\7:.^M^'YK:%%>Y1EDA#-M^8?XJ6'/'-;U%;M75B3Q
MSP=KR>&M7N(M0$T<$H$<BB/E)`W!8=1@%LX_*O7XY4FB26-U>-P&5E.0P/0@
M^E8^L^%=)UW+W5OLG/\`RWA^5^W7LW`QR#CMBN?A^'MU8R2G3_$5U:QR'[L<
M9!([;BKC.,^E9Q4HZ;CW.\HKBX_!FKB5#)XNU%D!&Y5+J2.^#O./RK2T3PA9
MZ!=M/97E]AQM>-W4HX[9&WMZ_P")JDY=A'15YE\2=&G%]'J\,"FV,:QS.@Y#
MY."WU!49]L>F?3:CDC2:)XI$5XW!5E89#`]01Z4YQYE8:.2^'NLQ7VAII[RY
MNK3(VL^2T>>"/89VX[8'3(KL*XR_^'>G2R13:9<2Z=-&P(*DN.,G(R<ANG.>
MW2HV\&:Z&0+XNO2"?G),@P,'I\_/./3^E2N9*S0'9R2I#$\LCJD:`LS,<!0.
MI)KPN\:X\0^([AK5)II+N=C$C<MMS\H/IA?P`%=_+X`O;S9'?^);RZMU<,8W
M1C^67(!P3SBNETCP_IFB1A;*V59,8:9OFD;IG+>G`.!Q[5,HN>^@+0OVT$=K
M;16\"[8HD"(N<X4#`%3445J(\6\"?\CGI_\`VT_]%M7M->=1_#!XI4EBUQDD
M0AE9;;!4CH0=]:'_``A>M?\`0X7_`.3_`/QRLH*45:PV=I2UQ7_"%ZU_T.%_
M^3__`!RNQCC$4:QJ6*J`H+,6/XD\G\:T3;W0B2J]Y9V]_:26MU$LL$HPZ-W_
M`,/KVJQ138'A_@^TM[[Q78V]U$LL+%BR,.#M1F&?Q`XKW"N)T+P#_8FLV^H_
MVGYWD[OW?D;<Y4KUW'UKMNU9TXN*U&PHHHK405Y/\3O^1EM_^O1?_0WKU>N3
M\3>"_P#A(]2CO/M_V?9"(MOD[\X8G.=P]:SJ)M60T;?A[_D6M*_Z\X?_`$`5
MI55T^T^P:;:V>_?Y$*1;\8W;5`SC\*M5:V$%<5\3O^1;MO\`K[7_`-`>NUK#
M\3Z!_P`)'IL=G]I^S[)A+O\`+WYP&&,9']ZIFFU9#1RGPK_YBW_;'_V>O1ZY
MOPKX5_X1G[7_`*;]I^T;/^66S;MW>Y_O5TE$$U&S!GG_`,1]`N+I8M7MD:00
M1^7.H/W4!R&`_%L_A[TOP^\1VG]F)I%S-'#/$Y$.X[1(K'.`2>6W,>/IUYKO
MJY/6?`&DZGF2U7[!/ZPK\AZ=4Z=!VQUYS4N+4N:('6T5P\?@C5X8DCC\6WJ1
MH`JJJN`H'0`>9TIW_"!37?R:KXBO[V`<K'DC#>OS%ATSV[U7-+L!VU%9FB:-
M#H6G_8K>:XEBWEU\YPQ7/88`P._U)J[<0_:+:6'S)(_,0IOC;:RY&,J>QJA#
MHY$E!:-U=0Q7*G(R#@CZ@@BH;O3[*_*?;+.WN-F=OG1*^W/7&?I7'S_##3&A
M86U[=QR_PM(5=1^``_G1-X-\0+Y?D>++Q\N`^]Y%VKW(^8Y/MQ]:B[ZH99UW
MP7X;6PN;MQ_9VW,C3QL=JGTVGC&2.%P>@%<!X/DO$\56"V3LKO(%D`(&Z/JX
M.?\`9!/X<<XKN&\`W5VR)J?B.]O+93N,1!ZX.""S,!U]*Z#1/#FG:##LLXLR
M'.Z>0`R,#V)QTX'`XXJ>1N5[6'<V****V)"O)_B+HGV'5EU*%,07?W\#A9!U
M[8Y'/J3NKUBJ&JZ5::S8/9WD>^-N01PR-V93V/\`GO43CS*PT9WA+Q`NOZ.L
MCG%W#B.<$C);'W\#LWTZY':N@KP^0:GX,\1L(V9)8F.TLORSQYXR,\J<>O!]
MQ7K>AZ_8^(+1I[)V!0X>*08=/3(]_P#/0U,)WT>X-&K1116H@HHHH`****`"
ML'Q7KJ:%HLLJR*MW*"ENN>2W][&#]W.>>.@[U9US7['P_:+/>NQ+G"11C+OZ
MX'M_GJ*\DD.I^,_$;&-6>65CM#-\L$>>,G'"C/IR?<UG.=M%N-(T?`.@R:EK
M27TL;?9+1M^_'#2#[JYSV^]WZ#/6O7ZH:5I5IHU@EG9Q[(UY)/+.W=F/<_Y[
M5?IPCRH&PHHKP_QY9_;_`-HCPU;?V;8ZCOTIO]$OVVPR8^T'YCL?IC(^4\@=
M.M6(]PHKPS5[V;PG\0](:QTC3K%"^R^TSPI=F>[FVQR.JR6Y6-60A\[O++``
MD.N5KW.@`HHK"\9W$UKX%\07%O+)#/%IMR\<D;%61A$Q!!'((/>@#=HKS_X)
M?\DAT+_MX_\`2B2O0*`"BBO&YK^9?C#J]AX]UM+32/L7FZ;9F\,%E-"9-H\P
M;UWOC<&1U8-\_P#"J@@'LE%>/_$*VT/PQI%Y_P`(?JO]E>)H[NWEBTK3+[;Y
M\C-&FTV8;:V5(.`F6VC.1G/J6DR7TNCV,NIP)!J#V\;7449RL<I4;U')X#9[
MGZF@"]115:]L+/4[.2SO[2"ZM9,;X;B,.C8.1E3P>0#^%`%FBO"]=\-Z%#^T
M7X9TN+1--33YM-=Y;1;6,12-MN.63&"?E7GV'I7L^FZ3IVCV[6^F:?:V,#/Y
MC1VL*Q*6P!DA0!G`'/M0!=HHHH`**\+OO[%C^,OC*?5K+PQ<NJ6:1#7M0%NJ
M@P*6V*T;AC\JY.`5X_O&O1_!$FA2VUXVD6GABVGWJ)TT"YCG4K@["[+&G.=^
M`1Z\]:`.MHHHH`**\N\<ZU?V/Q`T2UUVZGTOP;+N`N[.>2/S[DJ0J3RHRM"H
MSD8R#C)R,^7T&E6?P_TF6PO;!M#%U>2R?8[YYTEGNI&8A]LS$O(VYRI^8GG'
MM0!V-%%%`!17G_QM_P"20Z[_`-N__I1'6W!=>-5MXQ<:-H$DX0"1X]6F16;'
M)"FW)`SVR?J:`.EHKQ_]G'_DGM__`-A63_T5%7L%`!1110`4444`%%%>/_LX
M_P#)/;__`+"LG_HJ*@#V"BBB@`HKR?Q'H/\`;WQSCBBO9["^MO#0N+.\@/S0
M3"Y*ABO1U(9E93PRL1[CE/BAK7B*7X<-H/BGR[#6K:X29I4DQ!J]NK%"T>W@
MN&:-VC;:0`'`'W5`/H.BBB@`HJCJTE]%H]]+ID"3Z@EO(UK%(<+)*%.Q3R."
MV.X^HKRGP'=>&/$VBV0\9ZE'>>)4O9H[C3M7O7`%P7=5`M9&\O.UPH"I@'@<
M@X`/9**RM&GT)(YM,T.;3@E@Y26TL63%NQ8Y#(GW#N#<'N#6K0`445G?V[H_
M]L?V1_:MC_:?_/E]H3SON[ON9W?=YZ=.:`-&BBB@`HHHH`RM<T"Q\06BP7J,
M"ARDL9PZ>N#[_P">@KRC4=+UGP=JAEBEFC0$".ZB!"2#J%/;^'E3Z=QS7ME1
MR1)-$\4B*\;@JRL,A@>H(K.4%(:9PNC?$JVFQ%J\'V=_^>T(+)WZK]X=AW_"
MNTM=0LK_`'_8[RWN-F-WDRJ^W/3./I7)ZQ\.;"_N1-8S?8,Y\R-8]Z$YSD#<
M-OT''3@5R5UX$\1:;*)H(EF,0\T2VLO*D>@.&W<=A4\TX[JX:'L=%>+?\5I_
MU'__`"-1_P`5I_U'_P#R-1[7R"QZ_=:A96&S[9>6]OOSM\Z54W8ZXS]:XO6?
MB5;0YBTB#[2__/:8%4[=%^\>X[?C7-6O@7Q%J4IFGB6$RCS3+=2\L3Z@9;=S
MW%=/I/PTL[=EDU.X:Z;`_<QY1`<<Y.<GV^[T_"CFG+96#0Y*QT[6_&VK":>2
M1U^Y)=.GR1J.PQ@9Y^Z/7/J:]1T#0+3P]IXM[<;Y&P9IB/FD;^@]!V_,UJ1Q
MI#$D<:*D:`*JJ,!0.@`]*DJHPMJPN%%%%:""L[4]"TC6_*_M72;&_P#)SY?V
MJW279G&=NX'&<#\A6C10!6LK"STRSCL["T@M;6/.R&WC"(N3DX4<#DD_C5FB
MB@`HHHH`K65A9Z99QV=A:06MK'G9#;QA$7)R<*.!R2?QJS110`4444`5K*PL
M],LX[.PM(+6UCSLAMXPB+DY.%'`Y)/XU9HHH`****`*TUC9W%W;7<]I!)=6N
M[[/,\8+Q;AAMK=5R.#CK5FBB@`HHHH`QK[PGX<U.\DO+_P`/Z5=W4F-\T]E'
M([8``RQ&3P`/PJQIFA:1HGF_V5I-C8>=CS/LMND6_&<;MH&<9/YFM&B@`HHH
MH`*I6>E:;I]S<W%EI]K;3W;[[B6"%4:9LDY<@98Y8\GU-7:*`"BBB@"M>V%G
MJ=G)9W]I!=6LF-\-Q&'1L'(RIX/(!_"K-%%`%:RL+/3+..SL+2"UM8\[(;>,
M(BY.3A1P.23^-6:**`"BBB@`HHHH`*K65A9Z99QV=A:06MK'G9#;QA$7)R<*
M.!R2?QJS10`4444`5OL%G_:/]H?9(/MWE>1]I\L>9Y>=VS=UVYYQTS4>I:3I
MVL6ZV^IZ?:WT"OYBQW4*RJ&P1D!@1G!//O5VB@`HHHH`*K7MA9ZG9R6=_:07
M5K)C?#<1AT;!R,J>#R`?PJS10!#;P16EO';V\20P1($CCC4*J*!@*`.@`[5-
M110`5"((EN'N%A03R*J/)M`9E4L5!/<`LV!_M'UJ:B@`HHHH`****`"BBB@`
MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B
MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***
@*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@#_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
